Avadel Pharmaceuticals (AVDL) Short term Debt (2016 - 2022)
Historic Short term Debt for Avadel Pharmaceuticals (AVDL) over the last 13 years, with Q3 2022 value amounting to $26.3 million.
- Avadel Pharmaceuticals' Short term Debt changed N/A to $26.3 million in Q3 2022 from the same period last year, while for Sep 2022 it was $26.3 million, marking a year-over-year change of. This contributed to the annual value of $5.6 million for FY2019, which is 4115.9% down from last year.
- According to the latest figures from Q3 2022, Avadel Pharmaceuticals' Short term Debt is $26.3 million.
- Avadel Pharmaceuticals' Short term Debt's 5-year high stood at $26.3 million during Q3 2022, with a 5-year trough of $5.6 million in Q4 2019.
- For the 4-year period, Avadel Pharmaceuticals' Short term Debt averaged around $14.2 million, with its median value being $10.2 million (2018).
- Per our database at Business Quant, Avadel Pharmaceuticals' Short term Debt tumbled by 6536.5% in 2018 and then plummeted by 3088.62% in 2019.
- Quarter analysis of 4 years shows Avadel Pharmaceuticals' Short term Debt stood at $9.4 million in 2018, then tumbled by 41.16% to $5.6 million in 2019, then increased by 5.42% to $5.9 million in 2020, then surged by 349.17% to $26.3 million in 2022.
- Its Short term Debt stands at $26.3 million for Q3 2022, versus $26.2 million for Q2 2022 and $26.2 million for Q1 2022.